Best Peptides for Weight Loss in 2026: Evidence-Based Guide

The peptide landscape for weight loss has transformed dramatically. GLP-1 receptor agonists like semaglutide and tirzepatide have become the most prescribed weight loss medications in history, while research peptides like AOD-9604 and tesofensine are being studied for their fat-loss potential.

This guide ranks the best peptides for weight loss based on clinical evidence, FDA approval status, and documented efficacy.

FDA Status: Approved for weight management (Zepbound) and type 2 diabetes (Mounjaro)

Tirzepatide is the most effective FDA-approved weight loss peptide available today. A dual GLP-1/GIP receptor agonist, it was proven superior to semaglutide in the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025.

How it works: By targeting both GLP-1 and GIP receptors simultaneously, tirzepatide amplifies metabolic effects beyond what single-receptor agonists achieve.

Key evidence:

• SURMOUNT-1: 20.9% average weight loss at 15mg dose over 72 weeks
• SURMOUNT-5 (head-to-head): 20.2% weight loss vs 13.7% for semaglutide over 72 weeks
• SURMOUNT-3: 18.4% weight loss as add-on to lifestyle intervention

Administration: Weekly subcutaneous injection with a longer titration schedule. See our GLP-1 titration calculator for the full schedule.

FDA Status: Approved for weight management (Wegovy) and type 2 diabetes (Ozempic)

Semaglutide is the most widely prescribed GLP-1 agonist and has the longest track record of safety data among the newer weight loss peptides. The STEP clinical trials demonstrated average weight loss of 13-15% of body weight over 68 weeks.

How it works: Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity. It mimics the natural GLP-1 hormone released after eating.

Key evidence:

• STEP 1 trial: 14.9% weight loss vs 2.4% placebo over 68 weeks
• SELECT trial: demonstrated significant cardiovascular protection (reduced heart attacks and strokes)
• SURMOUNT-5: 13.7% weight loss vs 20.2% for tirzepatide in head-to-head comparison

Administration: Weekly subcutaneous injection with titration schedule starting at 0.25mg. Use our GLP-1 titration calculator for exact dosing.

Typical cost: $200-$400/month (compounded) or $1,000+/month (brand). Use our cost calculator to estimate your spend.

FDA Status: Approved for weight management

Liraglutide was the first GLP-1 agonist approved for weight loss. While less potent than newer options, it remains widely prescribed and has the longest safety track record.

How it works: Same GLP-1 mechanism as semaglutide but requires daily injection and achieves more modest weight loss.

Key evidence:

• SCALE trial: 8% average weight loss over 56 weeks
• Approved for adolescent obesity (ages 12+)
• 6+ years of post-market safety data

Administration: Daily subcutaneous injection, titrated from 0.6mg to 3.0mg over 4 weeks.

FDA Status: Phase 3 clinical trials (FDA approval anticipated ~2027)

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The Phase 3 TRIUMPH-4 trial results released in December 2025 showed the highest weight loss ever recorded for an obesity medication.

How it works: The addition of glucagon receptor activation increases energy expenditure and fat oxidation beyond what dual agonists achieve.

Key evidence:

• TRIUMPH-4 Phase 3 trial (Dec 2025): 28.7% average weight loss at 12mg dose over 68 weeks
• Significant reduction in liver fat and osteoarthritis pain
• Safety signal: dysesthesia (abnormal skin sensitivity) affected ~20% of users at the highest dose

Note: Not yet FDA-approved. Available only through clinical trials. If approved, retatrutide would surpass tirzepatide as the most effective weight loss peptide.

FDA Status: Research only (clinical development abandoned)

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) designed to stimulate fat metabolism without the growth-promoting effects of full HGH. It is heavily marketed by wellness clinics but has disappointing clinical data.

How it works: Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-burning portion of growth hormone.

Key evidence:

• 12-week trial: only 2.6 kg (5.7 lbs) average fat loss vs 0.8 kg placebo
• Failed to meet efficacy endpoints in longer 24-week trials — pharmaceutical development was abandoned
• No effect on blood sugar or growth (unlike full HGH)
• GRAS status from FDA for oral formulation
• Very high safety profile with virtually no side effects

Honest assessment: AOD-9604 is safe but clinically underwhelming. The weight loss is negligible compared to GLP-1 agonists. Most obesity medicine specialists do not consider it a viable standalone treatment.

Administration: Subcutaneous injection, typically 250-300mcg daily.

FDA Status: Not FDA-approved (approved in some markets outside the US)

Tesofensine is a serotonin-norepinephrine-dopamine reuptake inhibitor that was originally developed for Parkinson's and Alzheimer's but showed dramatic weight loss as a side effect.

How it works: Increases levels of serotonin, norepinephrine, and dopamine, reducing appetite and slightly increasing resting metabolic rate. It tackles both sides of the energy equation (calories in and calories out).

Key evidence:

• Phase 2/3 trials: ~10% body weight loss at 0.5mg daily over 24 weeks
• Significant appetite suppression
• Oral administration (no injection needed)

Administration: Oral capsule, 0.25-0.5mg daily. Higher doses (1.0mg) showed more weight loss but also more side effects including dry mouth and elevated heart rate.